Incyte Corporation Stock price

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
57.34 USD -1.76% Intraday chart for Incyte Corporation -5.68% -8.68%
Sales 2024 * 4.14B Sales 2025 * 4.61B Capitalization 12.87B
Net income 2024 * 838M Net income 2025 * 1.04B EV / Sales 2024 * 2.03 x
Net cash position 2024 * 4.47B Net cash position 2025 * 5.78B EV / Sales 2025 * 1.54 x
P/E ratio 2024 *
16.3 x
P/E ratio 2025 *
12.7 x
Employees 2,524
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.3%
More Fundamentals * Assessed data
Dynamic Chart
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says MT
Transcript : Incyte Corporation - Shareholder/Analyst Call
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) CI
Transcript : Incyte Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM
Wall Street: a flurry of records, including that of the Nasdaq 'broad CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'. CF
Knight Therapeutics Announces Launch of Minjuvi in Brazil MT
Jefferies Initiates Incyte With Buy Rating, Price Target is $81 MT
BMO Capital Adjusts Price Target on Incyte to $64 From $58, Keeps Market Perform Rating MT
Citigroup Adjusts Price Target on Incyte to $81 From $82, Keeps Buy Rating MT
JMP Securities Downgrades Incyte to Market Perform From Market Outperform MT
Truist Securities Adjusts Price Target on Incyte to $84 From $91, Maintains Buy Rating MT
Stifel Adjusts Price Target on Incyte to $68 From $67, Maintains Hold Rating MT
The market faces a choice Our Logo
RBC Lifts PT on Incyte to $65 From $63 on Model Updates Reflecting Monjuvi Integration, Slightly Improved Jakafi/Opzelura Sales Expectations; Sector Perform Kept MT
More news

Latest transcript on Incyte Corporation

1 day-1.76%
1 week-5.68%
Current month-1.75%
1 month-1.07%
3 months-5.41%
6 months-3.65%
Current year-8.68%
More quotes
1 week
57.30
Extreme 57.3
60.22
1 month
57.30
Extreme 57.3
61.87
Current year
56.10
Extreme 56.1
67.37
1 year
50.27
Extreme 50.27
76.04
3 years
50.27
Extreme 50.27
88.26
5 years
50.27
Extreme 50.27
110.37
10 years
40.30
Extreme 40.3
153.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 14-01-12
Director of Finance/CFO 53 19-02-10
President 60 23-06-04
Members of the board TitleAgeSince
Director/Board Member 57 00-12-31
Director/Board Member 71 19-12-15
Director/Board Member 70 15-01-19
More insiders
Date Price Change Volume
24-03-18 57.34 -1.76% 1,811,547
24-03-15 58.37 -0.29% 4,901,969
24-03-14 58.54 -0.64% 1,230,862
24-03-13 58.92 -0.69% 1,335,486
24-03-12 59.33 -2.40% 1,643,796

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.34 USD
Average target price
76.01 USD
Spread / Average Target
+32.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Incyte Corporation - Nasdaq